Novocure (NASDAQ: NVCR) — Perfil da empresa, notícias e dados financeiros
Novocure develops innovative therapies using Tumor Treating Fields technology to treat various types of cancer.
Novocure
Novocure (NASDAQ:NVCR) is a global oncology company dedicated to developing a novel platform technology, Tumor Treating Fields, to create therapies for various types of cancer. This technology uses electric fields to disrupt cancer cell division, potentially improving survival for patients. Novocure's operations span research, clinical development, and the commercialization of its products worldwide, aiming to transform cancer treatment through its innovative approach. Its flagship project involves the treatment of glioblastoma, a type of brain cancer, but the company is also exploring applications in other solid tumor cancers. Novocure's objectives focus on expanding the understanding and efficacy of Tumor Treating Fields, investing in clinical trials to explore new indications, and enhancing patient access to its treatments.
Resumo
Operações
Produtos e/ou serviços de Novocure
- Optune, a wearable medical device for the treatment of adult patients with glioblastoma multiforme.
- Optune Lua, designed for the treatment of malignant pleural mesothelioma.
- Tumor Treating Fields (TTFields) technology, utilizing electric fields to disrupt cancer cell division and inhibit tumor growth.
- Research in pancreatic cancer, exploring the use of TTFields to treat this type of cancer.
- Clinical trials for non-small cell lung cancer (NSCLC), investigating TTFields in combination with standard therapies.
- Development of innovative TTFields delivery systems, aimed at improving patient comfort and treatment adherence.
equipe executiva do Novocure
- William F. DoyleExecutive Chairman
- Frank LeonardCEO & Director
- Christoph BrackmannChief Financial Officer
- Michael PuriChief Human Resources Officer
- Uri WeinbergChief Innovation Officer & Chief Medical Officer
- Mukund ParavasthuChief Operating Officer
- Adam DaneyHead of Investor Relations
- Barak Ben-AryeGeneral Counsel
Principais indicadores financeiros
Resultados divulgados pela Novocure, em USD.
- Cap. de mercado
- 1,7 bi
- Receita (TTM)
- 699,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- -21.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 655,4 mi | -153,8 mi | -136,2 mi | |
| 605,2 mi | -170,5 mi | -168,6 mi | |
| 509,3 mi | -232,9 mi | -207 mi | |
| 537,8 mi | -89,5 mi | -92,5 mi |